Drug combo before surgery for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of pancreatic cancer that has not spread to other parts of the body but cannot be removed with surgery yet.
- You should be between 18 and 75 years old.
- Your overall health should be good enough to perform daily activities without assistance (ECOG 0 or 1).
- You must not have had any prior cancer treatment (chemotherapy, radiation, or targeted therapy) for this cancer.
- Your kidney, liver, and blood cell counts need to be within certain safe limits as determined by blood tests.
- You cannot have any other active cancer or serious heart, lung, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—surufatinib, chemotherapy (mFOLFIRINOX), and an immunotherapy (PD-1 inhibitor)—given before surgery to shrink tumors and improve outcomes for people with pancreatic cancer that is high-risk or borderline resectable.
This trial tests a combination of three drugs—surufatinib (a targeted therapy), camrelizumab (an immunotherapy), and a chemotherapy regimen called mFOLFOX6—as a second-line treatment for advanced pancreatic cancer. It's for people whose cancer progressed after first-line gemcitabine-based chemotherapy.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial tests adding surufatinib (a targeted therapy) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink or control the tumor better.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.